目的探究局部进展期乳腺癌新 辅助化疗中应用磁共振灌注成像的疗效, 并分析该方法作为化疗反应预测因子的可 行性。方法 12例乳腺癌患者依据新辅助 化疗后肿瘤体积的改变分为效应组和无效 应组,比较化疗前后最大信号丢失率、肿 瘤体积的变化以及化疗前最大信号丢失率 与肿瘤退缩率之间的相关性。结果 化疗 后,效应组的肿瘤平均体积(2.89±1.03) cm3,显著低于化疗前及无效应组化疗后肿 瘤体积,差异有统计学意义(P<0.05)；效 应组患者在接受新辅助化疗后,最大信号 丢失率为(13±11.2)%,显著低于化疗前及 无效应组化疗后相关指标。新辅助化疗一 个疗程后,两组患者间的灌注最大信号丢 失率改变的差异有统计学意义(P>0.05)。 最大信号丢失率的平均值与肿瘤体积的退 缩率之间呈正相关(r=0.313,P=0.44)。结 论 局部进展期乳腺癌辅助化疗可以应用 磁共振灌注成像技术进行早期的评价,但 需进一步深入的研究来佐证其是否可以作 为化疗反应的预测因子。

Objective To explore the clinical application of magnetic resonance imaging neoadjuvant chemotherapy of locally advanced breast cancer, and analyze the feasibility of the method as a predictor of response to chemotherapy. Methods 12 cases of patients with breast cancer after neoadjuvant chemotherapy on tumor volume change into effect group and ineffective group, the rate of change in tumor volume loss, maximum signal comparison before and after chemotherapy and chemotherapy before the maximum signal loss rate from a correlation between the rate and tumor. Results The effect of chemotherapy group, the average tumor volume of (2.89±1.03) cm3, significantly lower than that before chemotherapy and after chemotherapy the tumor volume of invalid should group, the difference was statistically significant (P< 0.05); group effect in patients receiving neoadjuvant chemotherapy, the maximum signal loss rate was (13±11.2)%, significantly below before chemotherapy and after chemotherapy should be related to invalid index group. Neoadjuvant chemotherapy after a period of treatment, loss rate change perfusion maximum signal between two groups was statistically significant (P> 0.05). There was a positive correlation between the shrinking rate of mean values of maximum signal loss rate and tumor volume (r=0.313, P=0.44). Conclusion Neoadjuvant chemotherapy of locally advanced breast cancer can be early evaluation of the application of magnetic resonance imaging technology, but need further study to prove whether it can be used as a predictor of response to chemotherapy.